Back to search

Article

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitors

2025-11-24

Abstract excerpt

FLT3 inhibitor efficacy in AML with FLT3-ITD is short-lived, frequently due to new mutations, most commonly in NRAS . Sphingosine kinase 1 (SPHK1), which phosphorylates sphingosine to generate sphingosine-1-phosphate (S1P), is upregulated and localized to the plasma membrane in RAS -mutated cells. We studied S1P and FLT3 co-targeting to overcome FLT3 inhibitor resistance in NRAS -mutated FLT3-ITD AML cells. NR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0048e504-68b8-5c63-8879-ae0a02e959b6
DOI
10.1101/2025.11.21.689510
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitorsDOI 10.1101/2025.11.21.689510
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.Semantic proximity
A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemiaSemantic proximity
Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistanceSemantic proximity
A Novel Function of Sphingolipid Signaling via S1PR3 in Hematopoietic and Leukemic Stem CellsSemantic proximity
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.Semantic proximity
Functional Characterization of FLT3 Receptor Signaling Deregulation in Acute Myeloid Leukemia by Single Cell Network Profiling (SCNP)Semantic proximity
Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.Semantic proximity
Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid LeukemiaSemantic proximity
A critical role for PLCG1 in RAS activation by BCR-ABL1 and FLT3-ITDSemantic proximity
Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.Semantic proximity
Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.